What are the ASCO guidelines for adjuvant endocrine therapy in the treatment of postmenopausal women with breast cancer?

Updated: Dec 27, 2019
  • Author: Pavani Chalasani, MD, MPH; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print
Answer

In its 2014 practice guidelines, ASCO addressed postmenopausal women and recommended they be offered adjuvant endocrine therapy with one of the following treatments [193, 194] :

Postmenopausal patients should be offered adjuvant endocrine therapy with one of the following treatments [193, 194] :

  • Tamoxifen for 10 years

  • An aromatase inhibitor for 5 years

  • Tamoxifen for 5 years, then switching to an aromatase inhibitor for up to 5 years

  • Tamoxifen for 2-3 years, then switching to an aromatase inhibitor for up to 5 years

Postmenopausal patients who are intolerant of either tamoxifen or an aromatase inhibitor should be offered an alternative adjuvant endocrine therapy. Patients who have received an aromatase inhibitor but discontinued treatment at less than 5 years may be offered tamoxifen for a total of 5 years. Patients who have received tamoxifen for 2-3 years should be offered an aromatase inhibitor for up to 5 years, for a total duration of up to 7-8 years of adjuvant endocrine therapy. [193, 194]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!